Credit: Pixabay/CC0 Public Domain University of Pittsburgh scientists have independently validated a new blood test platform that can simultaneously measure more than a hundred biomarkers of Alzheimer’s disease. The platform might improve clinicians’ ability to capture the multifaceted nature of Alzheimer’s pathology and streamline early disease diagnostics. The report is published in Molecular Neurodegeneration. “Alzheimer’s disease should not...
Tag: <span>Alzheimer’s disease</span>
Post
Understanding changes in pre-clinical Alzheimer’s disease: Study finds two proteins impact brain activity differently
September 18, 2024 by McGill University Credit: Jonathan Gallego RudolfAmyloid-beta and tau proteins have long been associated with Alzheimer’s disease. The pathological buildup of these proteins leads to cognitive decline in people with the disease. How it does that, though, remains poorly understood. A new study from the labs of Sylvain Baillet at The Neuro...
Post
New therapy that targets and destroys tau tangles: A promising Alzheimer’s disease treatment
September 13, 2024 by UK Research and Innovation Cells containing tau aggregates (green) before (left) and 13 hours after treatment with RING-nanobody (right). Credit: J. Benn – UK DRI at the University of CambridgeScientists have developed new potential therapies that selectively remove aggregated tau proteins, which are associated with Alzheimer’s disease, and improve symptoms of...
Post
Depression might sometimes be early sign of Alzheimer’s disease
August 30, 2024 by Ernie Mundell In some people, new-onset depression may stem from the same buildup of toxic plaques in the brain that have long been linked to Alzheimer’s disease, according to a new study. “Our findings provide additional support for depressive symptoms as an early feature of preclinical Alzheimer’s disease,” wrote a team...
Post
Alzheimer’s disease: It’s not only neurons—glial cells also produce harmful proteins
August 9, 2024 by Carmen Rotte, Max Planck Society Oligodendrocytes exhibit protein expression of amyloid precursor protein (APP) and an abundance of APP and BACE1 transcripts. Credit: Nature Neuroscience (2024). DOI: 10.1038/s41593-024-01730-3Memory loss, confusion, speech problems—Alzheimer’s disease is the most common cause of dementia, affecting about 35 million people worldwide, and the number is growing....
Post
HbA1c stability tied to lower risk for Alzheimer’s disease and related dementias
by Lori Solomon Increased glycated hemoglobin (HbA1c) stability within patient-specific target ranges is associated with a lower risk for Alzheimer’s disease and related dementias (ADRD), according to a study published online Aug. 2 in JAMA Network Open. Patricia C. Underwood, Ph.D., from the William F. Connell School of Nursing at Boston College, and colleagues examined...
Post
Accuracy of diagnostic blood tests for Alzheimer’s disease varies
July 30, 2024 by Washington University School of Medicine Determining performance of blood biomarker tests for amyloid pathology.Neurologists diagnose cognitive impairment with a clinical exam of memory and thinking skills. To determine whether Alzheimer’s disease is the cause of the cognitive impairment, evidence of the specific brain changes that characterize Alzheimer’s must be obtained, typically...
Post
Study identifies new biomarkers of Alzheimer’s disease
JULY 22, 2024 by Ingrid Fadelli , Medical Xpress Study overview. Credit: Nature Human Behaviour (2024). DOI: 10.1038/s41562-024-01924-6Recent advances in the study of proteomes (i.e., the entire range of proteins expressed by human cells and tissues) have opened new opportunities for identifying the biological markers of specific diseases or mental disorders. This could in turn...
Post
Artificial intelligence outperforms clinical tests at predicting progress of Alzheimer’s disease
JULY 12, 2024 by University of Cambridge Credit: Pixabay/CC0 Public DomainCambridge scientists have developed an artificially-intelligent tool capable of predicting in four cases out of five whether people with early signs of dementia will remain stable or develop Alzheimer’s disease. The team say this new approach could reduce the need for invasive and costly diagnostic...
Post
Automated prediction of Alzheimer’s disease progression using speech and machine learning
Boston UniversityJun 25 2024 Trying to figure out whether someone has Alzheimer’s disease usually involves a battery of assessments-;interviews, brain imaging, blood and cerebrospinal fluid tests. But, by then, it’s probably already too late: memories have started slipping away, long established personality traits have begun subtly shifting. If caught early, new pioneering treatments can slow...